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Abstract 
Myotonic dystrophy type I (DMI) is a multisystem disorder with 
a variable phenotype. The involvement of peripheral nerves in DM I 
disease is controversial. The DM I animal model DM300 transgenic 
mice that carry 350 to 500 CTG repeats express a mild DMI phe-
notype but do not exhibit motor or sensory pathology. Here, we 
investigated the presence or absence of peripheral neuropathy in 
transgenic mice (DMSXL) that carry more than I ,300 CTG repeats 
and display a severe form of DMI. Electrophysiologic, histologic, 
and morphometric methods were used to investigate the structure and 
function of peripheral nerves. We observed lower compound muscle 
action potentials recorded from hind limb muscles and slowing of 
sciatic nerve conduction velocity in DMSXL versus control mice. 
Morphometric analyses showed an axonopathy and neuronopathy in 
the DMSXL mice characterized by a decrease in numbers of myelin-
ated motor axons in sciatic nerve .and in spinal cord motor neurons. 
Pathologic alterations in the stmcture of hind limb neuromuscular 
junctions were also detected in the DMSXL mice. These results sug-
gest that peripheral neuropathy can be linked to a large CTG expan-
sion and a severe fonn of DM I. 
Key Words: Compound muscle action potential, DMSXL transgenic 
mice, Motor neuropathy, Myotonic dystrophy, Neuromuscular junc-
tions, Physical disector method. 
INTRODUCTION 
Myotonic dystrophy type I (DMI) is a multisystemic 
autosomal dominant disorder with a highly variable clinical 
phenotype (1, 2). The genetic basis for DM1 is the abnonnal 
amplification of a cytosine-thymine-guanine (CTG) trinu-
cleotide repeat in the 3' untranslated region of the DM protein 
kinase (DMPK) gene on chromosome 19q (3, 4). The number 
of DNA CTG repeats usually increases in successive gen-
erations of DM I families, and the size of triplet correlates 
with the severity of the disease_ In healthy individuals without 
DM I, 5 to 35 copies of repeat have been observed. Patients 
with CTG expansion containing 50 to 80 CTG repeats are 
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almost asymptomatic. Individuals with I 00 to I ,000 CTG 
repeats develop a disease in adult life (the classic form of 
OM!) that is characterized by progressive muscle wasting 
with myotonia. However, the most severe form of OM I is 
congenital disease; the mutation becomes unstable, and after 
3 to 4 generations, the CTG repeat lengthens to up to 2,000 
repeats (5). This fonn of disease is characterized by extreme 
myotonia and muscular atrophy (6). Other systemic manifes-
tations such as cataracts, cardiac conduction defects, endo-
crine dysfunction, respiratory failure, and changes in the CNS 
with mental retardation and hypersomnia are recognized as 
common extramuscular manifestations in patients with OM I 
(2, 7- 11). Although a number of clinical reports have drawn 
attention to the occasional presence of a peripheral neu-
ropathy in patients with OM I (J 2-16), other reports dispute 
completely the presence of neuropathy in patients (17-21 ). 
Therefore, additional studies are needed to determine the 
involvement of the peripheral nervous system (PNS) in OM I . 
During the last few years, the use of animal models for 
studying DMI mechanisms has become more frequent 
because access to the nervous system is only possible at the 
end stage of the disease. To investigate the primary involve-
ment of the PNS in DMI, we previously analyzed DM300 
transgenic mice carrying 350 to 500 CTG repeats and dis-
playing a mild DM l phenotype and found that those mice do 
not exhibit sensory or motor neuropathy (1). To explore this 
issue further, we examined new transgenic mice canying 
more than 1,300 CTGs and displaying more severe DMI 
features (22). 
MATERIALS AND METHODS 
All animal procedures were conducted according to 
local guidelines for care and use of experimental animals, and 
all analyses and measurements were performed blinded to 
animal genotype. 
Generation of DMSXl Transgenic Mice 
Production of transgenic mice carrying the human 
genomic OM I region with expanded repeats of approximately 
350 to 500 CTGs has been reported (23). The mice are of a 
mixed background. Heterozygous, homozygous, and wild-
type mice are obtained from the same litter. Recently, new 
transgenic mice carrying more than I ,300 CTG repeats were 
obtained, resulting from large expansions of the CTG repeat 
in successive generations. The newly generated mice (called 
DMSXL) display a severe phenotype: I) they are remarkably 
j Neuropathol Exp Neural • Volume 70, Number 8, August 201 1 
Copyright© 2011 by the American Association of Neuropathologists, Inc. Unauthorized reproduction of this article is prohibited. 
j Neuropathol Exp Neurol • Volume 70, Number 8, August 2011 
small; 2) they exhibit muscles abnormalities such as myotonia 
and muscle weakness; 3) they display abnormalities in the 
metabolism of multiple messenger RNAs, notably in brain, 
heart, and muscle; 4) their skeletal muscle showed abnomml 
splicing patterns for the insul in receptor and chloride channel 
I transcripts; 5) and they have a very high mortality rate, 
approximately 60% of them die before 7 months of age (22). 
Because heterozygous mice expressing a low Bevel of DMPK 
transcripts have no obvious phenotype (22), only homozygous 
transgenic mice were used. Wild-type mice from the same litter 
were analyzed because they provide the best controls. 
Electrophysiologic Studies 
Electrophysiologic investigations were carried out with 
a Viking TIT EMG machine (Nicolet Biomedical Inc, Madison, 
WI), using platinum subdermal electrodes (10 mm/30 gauge) 
for stimulation, recording, and grounding. Sixteen mice 
(8 DMSXL mice with a body weight of 22.19 ± 2.5 g and 8 wild-
type control mice with a body weight of31.75 ± 3.06 g), aged 
5 to 6 months, were studied. Each animal was anesthetized 
with ketamine (100 mg/kg) and xylazine (10 mg/kg) and fixed 
in the prone position. Right and left sciatic nerves were stimu-
lated to record the supramaximal motor responses or compound 
muscle action potentials (CMAPs) from hind! limb muscles 
(flexor digitorum brevis, gastrocnemius, and tibialis anterior), 
as previously described (24). Compound muscle action poten-
tial area and amplitude were measured using the negative peak 
and onset latency methods. To measure nerve conduction veloc-
ity (NCV) of the sciatic nerve, the stimulating electrodes were 
placed proximally near the sciatic nerve at the level of the limb 
girdle and distally at the level of the ankle with the recording 
electrodes placed just over the flexor digitorum brevis. 
Animal Perfusion and Tissue Preparation 
After electrophysiologic studies, the mice were deeply 
anesthetized and then transcardially perfused with 0.1-moi/L 
phosphate-buffered saline (PBS) containing 0. 1% heparin and 
0. 1% procaine, followed by a solution of 4% parafOtmalde-
hyde in 0.1-moVL PBS at pH 7.4. Sciatic nerves, lumbar 
spinal cord, and hind limb muscles (gastrocnemius and tibialis 
anterioris) were removed from each animal. To prepare 
cryostat sections, tissues were first cryoprotected in 30% 
sucrose overnight, frozen in liquid N2, and stored at -80°C. 
For semithin section preparat ion, the tissues were placed in 
2% Os04 in PBS for 3 hours, followed by dehydration in a 
series of graded ethanols and embedded in Epon (I, 25). 
Sciatic Nerve Section Analysis 
For histologic and morphometric analysis, 1-~J..m-th ick 
semithin transverse sections were cut from the common trunk 
of sciatic nerves and stained with toluidine blll!e. Neurolucida 
Software and Stereolnvestigator program (both from MBF 
Bioscience, Williston, VT) were used to measure the area of 
nerve cross sections and the diameter of myelinated axons and 
to count the total number of myelinated axons on I 0 nerve 
sections from 5 DMSXL an.d 5 wild-type control mice as 
described (1, 25). 
To count only myelinated motor fibers, cryostat sciatic 
nerve sections (12 ~J-rn) were prepared and double immuno-
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labeled with polyclonal anti-choline acetyltransferase anti-
body, which stains only myelinated motor fibers (ChAT, I :50; 
ABI44P, Millipore, Billerica, MA) and anti- neurofilament 
proteins (NF 200 kd, 1 :500; AB 1982, Millipore ), which stains all 
myelinated fibers. The sections were incubated with secondary 
antibody, Alexa Fluor 488 Donkey anti-goat I :200 (Invitrogen, 
Carlsbad, CA) and Cy3-conjugated donkey anti-rabbit (1 :500; 
Jackson Immuno Research, West Grove, PA). Myelinated motor 
fibers were colUnted on I 0 different sections (n = 5 for each 
mouse line) using an image-processing program (ImageJ 1.40; 
National Institutes of Health, Bethesda, MD) (I , 25). 
Analysis and Quantification of Motor Neurons 
in the Spinal Cord lumbar Enlargement 
The physical disector method was used to estimate the 
number of motor neurons in 2-mm segments of [umbar spinal 
cord (26). Adjacent cryostat transverse sections, 20 IJ-m thick, 
were prepared from lumbar spinal cord segments taken from 
5 wild-type and 5 DMSXL mice. Approximately 50 sampling 
sections, called disector pairs, were prepared from each ani-
mal, and every third disector pair was used to count the 
number of motor neurons. The sections were irnmunostained 
with anti-ChAT and were photographed; the images of each 
disector pair were carefully aligned using Adobe Photoshop 
and then imported into the lmageJ 1.40 program. Only ChAT-
positive neurons in the top section (tops) of the disector pair 
were marked and counted. The number of the tops was mul-
tiplied by 2 to estimate the number of neurons in the disector 
pair. Because we used every third disector pair, the number of 
neurons of each studied disector pair was multiplied by 3. 
Then the estimated number of neurons of 17 d isector pairs 
was combined to obtain the total number of motor neurons 
present in the 2-nun segment of lumbar spinal cord. All 
analyses and counts were performed blinded to the animal 
type. The results were exported to Microsoft Excel (Microsoft 
Corp, Redmond, WA) for statistical analysis. 
To investigate whether the surviving motor neurons of 
DMSXL mice express pathologic tau protein, cryostat spinal 
cord sections from control and DMSXL mice were incubated 
either with monoclonal antibody PHF-1 (developed by Dr 
Peter Davies, Albert Einstein College of Medicine, NY; dilu-
tion I :500), which specifically recognizes the phosphorylated 
serines 396 and 404 at the C-terminus of tau protein, or 
with A T8 monoclonal antibody (Thermo Fisher Scientific, 
Waltham, MA; dilution I: 1000), which recognizes the phos-
phorylated serines 199 and 202. Other sections were incubated 
with tau-! monoclonal antibody, which recognizes normal 
tau protein (produced by Dr Beat Riederer, University of 
Lausanne, Switzerland; dilution I: I 0). 
Analysis of Neuromuscular Junctions on Hind 
Limb Muscle Sections 
Serial cryostat longitudinal 20-~J..m-thick sections were 
prepared from hind limb muscles. First, the sections were 
incubated for 45 minutes in I j..Lg/mL tetramethyl rhodamine-
conjugated a -bungarotoxin (a-BTX; Invitrogen, Life Technol-
ogies) and then incubated ovemight with the primary polyclonal 
antibody anti-NF 200 kd (1:500; ABI982, Millipore), fol-
lowed by incubation with the secondary antibody conjugated 
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FIGURE 1. Representative reco rdings of compound muscle 
action potentials (CMAPs) in gastrocnemius muscle from wild-
type and DMSXL mice (left panels). The histogram of mean 
CMAPs (upper right panel) shows a significant decrease (42%) 
in CMAP amplitude in DMSXL mice versus wild-type 0NT; 
11.35 ± 1.11 vs 19.59 ± 2.92, **p < 0.01). The mean sciatic 
nerve conduction velocity is slightly reduced (14%) in DMSXL 
versus wild-type mice (33.28 ± 1 .37 vs 38.75 ± 0.46, **p < 0.01) 
(lower right panel). n = 8 mice/group. 
to Alexa Fluor 488 (Invitrogen) for 2 hours (1, 25). Muscle 
sections were observed by fluorescent microscopy (Axioplan 
2; Zeiss; Oberkochen, Germany) and photographed using an 
image-acquisition program (AxioYision with Axiocam HRc; 
Zeiss). Images were imported into the ImageJ 1.40 program to 
analyze all end plates (EPs) in the sections. To avoid counting 
and measuring the same junction twice, every third section 
was used. To determine whether the EPs are innervated, we 
followed the nerve fibers on several sections to determine 
whether if they made contact with the EP. The percentage of 
denervated EPs was estimated, and the morphometric param-
eters (area, shape complexity, and fluorescence intensity of 
rhodamine-a-BTX labeling) of every EP were measured and 
calculated as previously described in detai I (I , 24, 25). More 
than I ,400 EPs were measured rrom each mouse line (n = 6 
mice). All analyses and counts were perfonned blinded to the 
animal genotype. 
Statistical Analysis 
Results of DMSXL transgenic mice analysis were com-
pared with the values of wild-type control mice. The distribution 
of values was checked for normality, and transfonnations were 
applied when necessary. Then !-way analysis of variance was 
performed followed by the Holm-Bonferroni post hoc test. The 
distribution of diameters was compared using a i test. In all 
perfonned tests, p < 0.05 was considered significant. 
RESULTS 
Electrophysiologic Evidence of Peripheral 
Nerve Abnormality in DMSXL Mice 
Compound muscle action potentials and NCVs were 
recorded after sciatic nerve stimulation of both right and 
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left hind limbs from each DMSXL and wild-type mouse . 
Every DMSXL mouse examined exhibited a decrease in both 
CMAP parameters and NCY. In DMSXL mice, the amplitude 
of CMAPs recorded from gastrocnemius muscles was greatly 
reduced (42%) ·compared with controls (Fig. I). There was a 
similar significant fall in CMAP (38.86%) in tibialis anterior 
muscles. Moreover, a slowing (14%) of sciatic NCV was 
observed in DMSXL compared with control m[ce (Fig. l). 
Although the decrease in NCV is slight, it is significant 
(p < 0.0 I). To rule out the possibility that the reduction in 
CMAP and NCV in DMSXL mice was due to the small size 
and weight of these transgenic mice, we measured the CMAP 
and the NCY in control mice that had a similar size and 
weight range to the DMSXL. The results demonstrated that 
the reduction in CMAP and NCY in DMSXL mice was 
independent of the size and the weight of the mouse. The 
reduction in CMAP and NCY in DMSXL indicates muscle 
and nerve dysfunction. 
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FIGURE 2. Sciat ic nerve histology and morphometry. (A- D) 
Transverse semithin sections of sciatic nerve stained with tolu-
idine blue from wild-type 0NT) control mice (A, C) and DMSXL 
mice (8, D). The low (A, B) and high (C, D) magnifications 
show no obvious structural abnormality in DMSXL sciatic nerves. 
( E) Surface area measurements of nerve sections (from 5 con-
trol and 5 DMSXL mice) reveal that mean sciatic 111erve section 
area is significantly smaller in DMSXL mice (0.113 ± 0.01 1 vs 
0.156 ± 0.016 mm2, **p < 0.01 ). (F) The size-frequency dis-
tribution of myelinated axon diameters demonstrates that the 
peak axon diameter in DMSXL mice is shifted to the left, that is, 
trend to smaller diameters (p < 0.001 ). 
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FIGURE 3. Cryostat sciatic nerve cross sections double immunolabeled for neurofilament (NFH) (myelinated axons, red), and 
anti-choline acetyl transferase (ChAT) (myelinated motor axons, green). In both control and DMSXL mice, low and high magni-
fications show numerous axons immunolabeled with NFH and not stained with ChAT. Counts of only ChAT-positive axons on 5 
nerve sections from 5 wild-type and 5 DMSXL mice revealed a loss of 19% of myelinated motor axons in DMSXL mice. 
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FIGURE 4. Estimation of moto·r neuron numbers in lumbar spinal cord by the physical disector method. Twenty-micrometer-thick 
adjacent cryostat transverse sections were prepared from lumbar spinal cord from 5 wild-type (WT) and 5 DMSXL mice. Seventeen 
disector pairs were analyzed from each animal. Sections were immunolabeled with an anti- choline acetyl transferase (ChAT) 
antibody. (A- C) Micrographs of 1 disector pair: top section (A) and bottom section (B). The ChAT-immunolabeled neurons in the 
top section of the disector pair are marked in red and those in the bottom section are marked in yellow. The marks of the motor 
neurons in the bottom section are superimposed on the top section (C); arrows indicate the tops (i.e. neurons present only in the 
top section). The histogram shows that the mean estimated number of motor neurons in DMSXL mice is significantly smaller than 
in controls (**p < 0.01 ). 
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Axonopathy and Muscle Dystrophy Underlie 
the Electrophysiologk Abnorm()lity 
in DMSXL Mice 
Although the general cytoarchitecture of sciatic nerves 
did not differ noticeably between DMSXL and control mice, 
the mean area of nerve section in DMSXL mice was smaller 
than in control mice (0.113 ± 0.0 II vs 0.156 ± 0.016 mm2, 
p < 0.01) (Figs. 2A-E). Moreover, the diameter of myelinated 
fibers in DMSXL sciatic nerves was smaller, and the thickness 
of myelin sheath was reduced (19%). The size-frequency 
histogram based on the measurement of approx imately I ,500 
fibers from each mouse line showed that the peak axon 
diameter in DMSXL mice was significantly shifted to a 
smaller diameter versus that in wild-type mice (p < 0.00 I) 
(Fig. 2F). In addition, the number of all myelinated fibers in 
sciatic nerves in DMSXL mice was reduced by 6%. Never-
theless, counts of ChAT-positive axons on sciatic nerve sec-
tions double immunolabeled for ChAT and NF revealed a loss 
of approximately 19% of myelinated motor axons in DMSXL 
mice (Fig. 3). Because myelinated motor axons represent only 
22% of the total number of myelinated axons, the loss of 6% 
of the total number of myelinated fibers corresponds to a 
preferential loss of motor axons. Together with the morpho-
metric results, these observations indicate the presence of an 
axonopathy in DMSXL sciatic nerves with a specific loss of 
large myelinated fibers. These results were independent of 
the size and weight of the mice. 
Evidence of Motor Neuronop()thy in the 
lumbar Spinal Cord of DMSXL Mice 
To verify whether the loss of motor axons observed in 
DMSXL mice resulted from only a degeneration of myelin-
ated motor axons ("dying baclk neuropathy") or rather from 
neuronopathy that affects neuron cell bodies, we used the 
physical disector method to estimate the number of motor 
neurons in lumbar enlargement of spinal cord (!Fig. 4). There 
was a 24% reduction in the number of motor neurons in 
DMSXL mice versus controls (I ,348 ± 49 vs I ,758 ± 79, 
p < 0.01). These results indicate that the lumbar motor 
neurons in DMSXL mice are affected by a neuronopathy. 
Because tau abnormalities are found in brain neurons of 
DM patients, we perfonned immunohistochemical staining 
for pathologic and normal tau proteins. Incubation of spinal 
cord sections with PHF-1 or AT8 antibodies demonstrated that, 
in DMSXL mice, most surviving motor neurons displayed a 
strong immunostaining (Figs. 58, D), whereas in control 
wild-type mice, all motor neurons were PHF-1 and AT8 
negative (Figs. SA, C). In contrast, the normal tau protein was 
highly expressed in control motor neurons compared with 
DMSXL motor neurons (Figs. SE, F). A link between over-
expression of a kinase in DM brain neurons and the presence 
of abnormal tau protein has been reported (27). 
Pathologic Changes in the Structure of 
Neuromuscular junction.s in DMSXL Mice 
Histologic examination .of gastrocnemius muscle sec-
tions labeled with rhodamine-a-BTX and NF antibody 
showed that control mice displayed EPs with a typical pretzel 
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FIGURE 5. Immunocytochemical detection of pathologic 
hyperphosphorylated and normal tau proteins in spinal cord 
motor neurons. (A- E) Cryostat sections from lumbar spinal 
cord of wild-type {A, C, E) and DMSXL mice (B, D, F) 
immunostained with PHF-1 (A, B), AT8 (C, D), or tau-1 (E, F) 
antibodies. Pathologic hyperphosphorylated tau proteins are 
highly expressed in motor neurons in DMSXL mice as demon-
strated by strong PHF-1 (B) or AT8 (D) staining. Wild-type 
mice motor neurons do not show visible PHF-1 (A) or AT8 (C) 
staining. Normal tau protein is intensely expressed in wild-type 
motor neurons (E) and is faintly expressed in DMSXL motor 
neurons (F). Data are representative of 5 mice/group. 
shape and strong fluorescent labeling, with 98% of them 
in direct contact with the nerve terminal (Figs. 6A-C). In 
DMSXL mice, however, numerous EPs exhibited lengthened 
shapes and faint labeling, and only 77% had axonal terminal 
contact (Figs. 6D-F). Morphometric analysis showed a sig-
nificant decrease in the size (16.4%) and shape complexity 
( 17.5%) ofEPs in DMSXL mice (Figs. 6G, H). Moreover, the 
concentration of acetylcholine receptors on postsynaptic 
membranes assessed by measuring the a -BTX fluorescence 
labeling intensity was reduced by 23% (Fig. 6T). 
DISCUSSION 
Involvement of the CNS and other organs in patients 
with DM I is well known, but PNS involvement in DM I 
remains controversial. Clinically, the diagnosis of peripheral 
neuropathy in patients with DM l is mainly detected by elec-
trophysiologic tests and supported by neurologic examination. 
Several reports have described a reduction in CMAP, a 
slowing of maximal and minimal motor NCV, or an increase 
in the minimal latency of F waves in DM patients, suggest-
ing the presence of pathologic changes in peripheral nerves 
© 20 II American Association of Neuropathologists, Inc. 
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FIGURE 6 . Representative micrographs of gastrocnemius muscle cryostat sections stained with rhodamine--a-bungarotoxin (red) 
and neurofilament antibody (green). (A- F) In wild-type mice (WT), nearly all end plates (EPs) are innervated by branches of axons 
(A, B). End plates without any contact to axon terminals are easily identified in DMSXL mice (D, E) . At higher magnification, 
representative images illustrate a single EP (C, F) . In a DMSXL mouse (F), the EP has a smaller size and a less complex shape than 
that in a control mouse (C). (G-1) The mean surface area of EPs, the shape complexity, and the density of acetylcholine receptors 
on postsynaptic membranes labeled with rhodamine-a-BTX (fluorescence intensity) are represented in the 3 histograms. More 
than 1 ,400 EPs were measured from each mouse line. All 3 parameters were smaller in DMSXL mice versus WT control mice 
(*p < 0.05). 
(12-16, 28-33). Indeed, a few histopathologic studies of 
peripheral nerves and muscle biopsies have confinned the 
presence of peripheral neuropathy in patients with DM I 
(34-40). Some authors who support the presence of neuro-
pathy in DM I argue that pathologic changes and peripheral 
nerve dysfunction are primary and are unrelated to the glucose 
intolerance (which may be present in some patients with 
DM I) or to other metabolic, nutritional, or genetic factors 
( 12, 31, 41 ). The absence of impainnent of nerve conduction 
in patients with DM I has aDso been reported ( 17, 19, 21 ). 
These and other authors found no evidence of morpho-
logic abnormality of peripheral nerves, no signs of muscles 
denervation, and no loss in the number of motor neurons in 
© 2011 American Association ofNeuropathologists, Inc. 
patients with DM I ( 18, 20, 21 ). It is important to emphasize 
that studies confirming or denying association of peripheral 
neuropathy with DM I disease involved patients of unknown 
genotype because the molecular basis of DM 1 was not yet 
identified when those reports appeared. Consequently, the 
earlier studies did not take into consideration the relationship 
between the expansion of the CTG repeat and the severity of 
the clinical features. Therefore, we believe that the conflicting 
results are probably due to different lengths ofCTG repeats in 
the patients. 
We previously studied transgenic mice (DM300) cany-
ing 350 to 500 CTG repeats and displaying mild DM I features 
(23, 42), and analysis of the sciatic nerve, lumbar dorsal root 
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ganglia, and spinal cord of those mice revealed neither axon-
opathy nor neuronopathy (I). Moreover, no signi:ficant changes 
can be detected either in CMAP index or in NCV in DM300 
transgenic mice (43). These results suggest that the length of 
CTG repeats (350-500) probably was not sufficient to induce 
peripheral neuropathy in that mouse model (I). 
Because CMAP amplitude represents the total number 
of stimulated axons and NCV provides information about the 
rate at which a neural impulse propagates along myelinated 
fibers (44), the reduction in CMAP amplitude and NCV 
detected in DMSXL mice indicates nerve dysfunction. This 
correlates with clinical studies that found peripheral nerve 
dysfunction in patients with DMI (12-16, 29, 32, 33). 
Structural pathologic changes that probably caused the dys-
function of peripheral nerves in the mice were detected in 
sciatic nerves, lumbar motor neurons, and neuromuscular 
junctions. ln particular, the s ize-frequency distribution of 
myelinated fiber diameters indicates that the 6% reduction in 
the total number of myelinated fibers in DMSXL mice was 
essentially a loss of large axons, which correspond to motor 
fibers in sciatic nerve (45). The reduction of 19% of ChAT-
positive axons confirmed a preferential loss of motor axons, 
and the decrease in the number of motor neuron cell bodies 
indicates the presence of a motor neuronopathy. Moreover, 
the higher expression of hyperphoshorylated tau protein in 
DMSXL mice motor neurons argues for increased kinase 
activity (27). It is worth noting that comparable motor neu-
ronopathy and pathologic changes in neuromuscular junctions 
have been described in patients with DM I (46). Indeed, 
Wheeler et al. (46) demonstrated the presence of ribonuclear 
foci in motor neurons spinal cord autopsy and the high 
expression of CUGexp RNA and sequestration of MBNLI 
protein in postsynaptic nuclei of neuromuscular junctions in 
muscle biopsies. Other studies have emphasized that dramatic 
changes in talll isoform expression in brain neurons is asso-
ciated with the presence of large CTG expansion in the brains 
of patients with DM1 (27, 47-49); the expanded! CUG repeats 
may affect RNA metabolism of several genes and act as a 
gain-of-function mutation (48). 
We believe that the motor neuropathy detected in 
DMSXL mice is independent of possible alterations in the 
thyroid or pancreatic [3-cell ftmction because the DM300 trans-
genic mice used to generate DMSXL mice did not develop 
either motor or sensory neuropathy (I). Moreover, the neu-
ropathy detected in DMSXL transgenic mice showed a loss in 
the number of motor neurons, whereas neuropathies induced 
by hypothyroudism or diabetes are mainly characterized by a 
deficiency in myelination and progressive distal loss of axonal 
terminals but without perikaryal loss (50, 51). Our data are 
consistent with other studies demonstrating a selective loss 
of functioning motor units and alterations of neuromuscular 
excitability in patients with OM I (52-55). 
Genotype-phenotype correlation studies anso report that 
muscular disability and the severity of hand muscle myotonia 
depend on the CTG repeat length in leukocyte DNA (56- 61). 
The severity of cardiac conduction abnormalities and arrhyth-
mia in DMl is also directly related to age and CTG repeat 
length (62). Moreover, an association between the CTG repeat 
size and cognitive impairment has been described (63, 64). 
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Because transgenic mice carrying 350 to 500 CTG repeat did 
not have peripheral neuropathy ( 1), whereas DMSXL mice 
undoubtedly have motor neuropathy, we conclude that there 
is a correlation between the development of neuropathy in 
DM I transgenic mice and the size of the CTG triplet. However, 
it should be noted that the relationship between the length of 
the CTG repeat and the severity of DM 1 features does not 
always hold true, and there are some exceptions. Indeed, some 
authors claim that cataract, gastrointestinal, respiratory insuffi-
ciency sleep disorder, and other OM features are not correlated 
with the length of the CTG triplet (56, 58). Because in DM !-
affected individuals the instability of the triplet repeats induces 
somatic heterogeneity characterized by a variable size in dif-
ferent tissues, some investigators hypothesize that the somatic 
mosaicism might be one possible explanation for the lack of 
precise correlation between the number of CTG repeats in 
leukocyte DNA and the severity of DM I in its multisystemic 
aspect. 
In conclusion, analyses of DMSXL transgenic mice 
carrying a large CTG expansion and expressing a severe DMI 
phenotype provide evidence that these mice have a motor 
neuropathy that we infer to be linked to their large CTG 
expansion. In the future, we will investigate whether sensory 
neuropathy can also be linked to the long CTG repeat and 
severe fonn of DM I. 
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